ArticleBMC psychiatry2025
Exploring risky decision-making dynamics during antidepressant treatment in major depressive disorder: a computational modeling approach.
Article in BMC psychiatry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundPatients with major depressive disorder (MDD) show greater loss sensitivity and higher delayed discounting rates during decision making, but findings regarding their risk preferences are inconsistent. Computational behavioral modeling provides a promising tool for the investigation of these latent factors underlying the decision-making behaviors.
objectivesConduct both cross-sectional and longitudinal analyses to identify patterns and changes in risky decision-making over time, examine correlations between traditional CGT performance indicators and cognitive modeling parameters to better understand the underlying mechanisms of decision-making, and separately explore participants' reward and loss sensitivities.
methodsAt baseline, 52 patients with MDD and 66 healthy controls (HCs) underwent psychometric assessment and performed the Cambridge gambling task (CGT) characterizing risky decision-making behavior. After 8 weeks of treatment with the selective serotonin reuptake inhibitor, the patient group underwent assessment and performed the CGT again. Applying a cumulative model to the trial-by-trial behavioral data of the CGT, we also compared the latent factors between groups, including probability distortion, color bias, utility/loss sensitivity, delayed reward discounting and choice consistency.
resultsPatients with MDD had more depressive symptoms and anhedonia than did HCs. MDD group exhibited both greater delayed reward discounting and lower choice consistency than HCs. After the treatment, MDD group had both decreased loss sensitivity and color choice bias. Controlling for depressive symptoms, a deficit in consummatory pleasure with motivational drive was associated with greater delayed reward discounting at baseline in MDD group.
conclusionsOur findings suggest that patients with MDD have deficits in reward function (higher delayed reward discounting and lower risk adjustment) at baseline. With antidepressant treatment, loss sensitivity decreased while impairment in reward function persists, and these patients tend to make more risky choices after treatment.
trial registrationThe registration number is ChiCTR2000031931 and date of registration is April 15th 2020.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.